ACID REDUCER TABLET

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

RANITIDINE (RANITIDINE HYDROCHLORIDE)

זמין מ:

APOTEX INC

קוד ATC:

A02BA02

INN (שם בינלאומי):

RANITIDINE

כמות:

75MG

טופס פרצבטיות:

TABLET

הרכב:

RANITIDINE (RANITIDINE HYDROCHLORIDE) 75MG

מסלול נתינה (של תרופות):

ORAL

יחידות באריזה:

10

סוג מרשם:

OTC

איזור תרפויטי:

HISTAMINE H2-ANTAGONISTS

leaflet_short:

Active ingredient group (AIG) number: 0115150003; AHFS:

מצב אישור:

APPROVED

תאריך אישור:

2013-10-24

מאפייני מוצר

Page
1
of
33
PRODUCT MONOGRAPH
ACID REDUCER
Ranitidine Tablets USP
75 mg and 150 mg Ranitidine (as Ranitidine Hydrochloride)
Histamine H
2
-receptor antagonist
APOTEX INC.,
Date of Revision:
150 Signet Drive
January 24, 2020
Toronto, Ontario
M9L 1T9
Submission Control No.: 238800
Page
2
of
33
TABLE OF CONTENTS
_ _
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
............................................................................
3
INDICATIONS AND CLINICAL USE
.................................................................................
3
CONTRAINDICATIONS
.......................................................................................................
3
WARNINGS AND PRECAUTIONS
.....................................................................................
4
ADVERSE REACTIONS
.......................................................................................................
5
DRUG INTERACTIONS
........................................................................................................
7
DOSAGE AND ADMINISTRATION
...................................................................................
9
OVERDOSAGE
....................................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
................................................................ 10
STORAGE AND STABILITY
..............................................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 15
PART II: SCIENTIFIC INFORMATION
..................................................................................
17
PHARMACEUTICAL INFORMATION
.............................................................................
17
DETAILED PHARMACOLOGY
.........................................................................................
18
TOXICOLOGY
.............